Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include Halneuron, which is in late-stage clinical development for the treatment of chemotherapy-induced neuropathic pain; IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia; and IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is headquartered in Alpharetta, Georgia.